ESMO 2019 Bladder Cancer

Viewing 1-20 of 31 articles

ESMO 2019: Invited Discussant: How Do the Results of IMvigor130 Change Things in Bladder Cancer?

ESMO 2019: Invited Discussant: IMvigor130: Phase III Study of Atezolizumab with or without Platinum-Based Chemotherapy in Previously Untreated Metastatic Urothelial Carcinoma

ESMO 2019: EV-103 Enfortumab Vedotin plus Pembrolizumab for Urothelial Carcinoma

ESMO 2019: Invited Discussant: Results of the IMVigor130 Study of Atezoluzumab as Monotherapy, or in Combination with Platinum Chemotherapy for Patients with Advanced or Metastatic Urothelial Carcinoma

ESMO 2019: Immune Therapy in Combination with Targeted Therapy

ESMO 2019: IMvigor130: Efficacy and Safety of Atezolizumab as Monotherapy or Combined with Platinum-based Chemotherapy vs Placebo + Platinum-based Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

ESMO 2019: IMvigor130: Efficacy and Safety from a Phase 3 Study of Atezolizumab as Monotherapy or Combined with Platinum-based Chemotherapy vs Placebo + PBC in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

ESMO 2019: IMvigor130: Efficacy and Safety from a Phase 3 Study of Atezolizumab as Monotherapy or Combined with Platinum-based Chemotherapy versus Chemotherapy alone in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

ESMO 2019: The NABUCCO Study, Pre-operative Ipilimumab and Nivolumab in Locoregionally Advanced, Stage III, Urothelial Cancer

ESMO 2019: Invited Discussant: (904PD, 905PD, 906PD) NABUCCO (mUC), FGFR3 Alteration as a Predictor of Non-Response to Neoadjuvant Pembrolizumab (mUC), and Adjuvant Sunitinib in Patients with High-Risk (RCC)

ESMO 2019: Immune Therapy in Combination with Chemotherapy

ESMO 2019: Single Agent Immune Therapy and Immune Combinations

ESMO 2019: Erdatitinib versus Available Therapies in Advanced Urothelial Cancer: A Matching Adjusted Indirect Comparison

ESMO 2019: Hyperphosphatemia Due to Erdafitinib and Anti-tumor Activity Among Patients with Advanced Urothelial Cancer

ESMO 2019: Multiple-cohort Analysis Investigating FGFR3 Alteration as a Predictor of Non-response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer - A Medical Oncologist's Perspective

ESMO 2019: Pre-Operative Ipilimumab and Nivolumab in Locoregionally Advanced, Stage III, Urothelial Cancer - NABUCCO

ESMO 2019: FGFR3 Alteration as a Predictor of Non-Response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer

ESMO 2019: Multiple-cohort Analysis Investigating FGFR3 Alteration as A Predictor of Non-response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer

ESMO 2019: Pre-operative Ipilimumab and Nivolumab in Locoregionally Advanced, Stage III, Urothelial Cancer (NABUCCO) 

ESMO 2019: Invited Discussant for EV-103: Initial Results of Enfortumab Vedotin plus Pembro and of BISCAY, an Adaptive, Biomarker Directed Platform study in Metastatic Urothelial Cancer

1
2